Immune system and bone microenvironment: rationale for targeted cancer therapies.
antiandrogens
bisphosphonates
bone niche
immune system
osteoimmunology
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
28 Jan 2020
28 Jan 2020
Historique:
received:
09
10
2019
accepted:
31
12
2019
entrez:
18
2
2020
pubmed:
18
2
2020
medline:
18
2
2020
Statut:
epublish
Résumé
Osteoimmunology was coined about twenty years ago to identify a strict cross talk between bone niche and immune system both in physiological and pathological activities, including cancer. Several molecules are involved in the complex interaction between bone niche, immune and cancer cells. The Receptor Activator of NF-kB (RANK)/RANK Ligand (RANKL/Osteoprotegerin (OPG) pathway plays a crucial role in bone cells/cancer interactions with subsequently immune system control failure, bone destruction, inhibition of effect and metastasis outcome. The bidirectional cross talk between bone and immune system could became a potential target for anticancer drugs. Several studies evidenced a direct anticancer role with improved survival of bone-targeted therapies such as bisphosphonates and RANKL antagonist Denosumab. Conversely, initial data evidenced a possible anti-bone resorption effect of systemic anticancer drugs through and immunomodulation activity, i.e. new generation antiandrogens (Abiraterone) in prostate cancer. All data could open a future rationale of combined bone, immunologic and targeted therapies in cancer treatment.
Identifiants
pubmed: 32064051
doi: 10.18632/oncotarget.27439
pii: 27439
pmc: PMC6996902
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
480-487Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST None.
Références
Nat Med. 2006 Dec;12(12):1372-9
pubmed: 17143276
Oncotarget. 2016 Oct 11;7(41):67142-67149
pubmed: 27613839
Eur J Cancer. 2016 Jan;53:75-83
pubmed: 26693901
Hum Immunol. 2013 Jul;74(7):861-6
pubmed: 23619471
Cancer Res. 2001 Jun 1;61(11):4432-6
pubmed: 11389072
Blood. 2005 Aug 1;106(3):852-9
pubmed: 15817678
Expert Opin Biol Ther. 2014 Jan;14(1):15-26
pubmed: 24161019
Crit Rev Oncol Hematol. 2017 Dec;120:227-233
pubmed: 29110971
Eur J Immunol. 2008 Oct;38(10):2845-54
pubmed: 18958885
Int J Mol Sci. 2019 May 27;20(10):
pubmed: 31137764
Nature. 2003 Oct 23;425(6960):841-6
pubmed: 14574413
Blood. 2007 May 1;109(9):3706-12
pubmed: 17227831
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Clin Dev Immunol. 2013;2013:720504
pubmed: 23935650
Arch Biochem Biophys. 2014 Nov 1;561:13-21
pubmed: 25282390
Nature. 2006 Mar 30;440(7084):692-6
pubmed: 16572175
Am J Anat. 1985 Feb;172(2):141-53
pubmed: 3976544
Cancer Res. 2018 Jul 15;78(14):3913-3925
pubmed: 29752261
Nat Med. 2012 Aug;18(8):1224-31
pubmed: 22820642
Cent European J Urol. 2011;64(4):201-4
pubmed: 24578893
Anticancer Agents Med Chem. 2012 Feb;12(2):102-13
pubmed: 21864232
Br J Clin Pharmacol. 2019 Jun;85(6):1114-1124
pubmed: 30601585
Nat Rev Immunol. 2007 Apr;7(4):292-304
pubmed: 17380158
Osteoarthritis Cartilage. 1999 Jul;7(4):419-21
pubmed: 10419786
Blood. 2014 Oct 30;124(18):2834-46
pubmed: 25139351
J Exp Med. 2012 Mar 12;209(3):537-49
pubmed: 22351931
Arthritis Rheum. 2006 Nov;54(11):3551-63
pubmed: 17075861
Ann N Y Acad Sci. 2006 Apr;1068:367-401
pubmed: 16831938
Arthritis Res Ther. 2012 Nov 13;14(6):R246
pubmed: 23148681
PLoS One. 2013 Dec 30;8(12):e83026
pubmed: 24386138
J Clin Invest. 2000 Sep;106(6):749-52
pubmed: 10995785
Support Care Cancer. 2016 Jan;24(1):447-455
pubmed: 26335402
Clin Cancer Res. 2011 Aug 1;17(15):4936-41
pubmed: 21593194
Endocrinology. 2001 Dec;142(12):5050-5
pubmed: 11713196
Cancer Immunol Immunother. 2011 Mar;60(3):305-17
pubmed: 21243489
J Clin Invest. 2005 Dec;115(12):3418-27
pubmed: 16294221
Clin Cancer Res. 2013 Dec 15;19(24):6863-72
pubmed: 24166910
J Exp Med. 2002 Sep 2;196(5):705-11
pubmed: 12208884
Cancer Res. 2010 Oct 1;70(19):7610-9
pubmed: 20841471
Bone. 2003 Jan;32(1):1-7
pubmed: 12584029
Nature. 2010 Nov 4;468(7320):98-102
pubmed: 20881962
BMC Cancer. 2019 Feb 26;19(1):176
pubmed: 30808421
PLoS One. 2012;7(6):e40044
pubmed: 22768215
J Oncol. 2014;2014:625060
pubmed: 24795759
Inflammation. 2014 Jun;37(3):657-69
pubmed: 24287823
Int J Cancer. 2001 Apr 1;92(1):96-105
pubmed: 11279612
Stem Cells. 2012 Apr;30(4):762-72
pubmed: 22267310
J Bone Oncol. 2019 Jul 16;18:100252
pubmed: 31440444
Blood. 2000 Sep 1;96(5):1873-8
pubmed: 10961889
Ann N Y Acad Sci. 2012 Aug;1263:29-40
pubmed: 22831177
Annu Rev Immunol. 2002;20:795-823
pubmed: 11861618
Cell Oncol (Dordr). 2018 Apr;41(2):107-121
pubmed: 29470831
Oncologist. 2013;18(4):353-61
pubmed: 23404816
Cancer. 2004 Jun 15;100(12):2613-21
pubmed: 15197804
Immune Netw. 2018 Feb 07;18(1):e8
pubmed: 29503739
Blood. 2004 Dec 1;104(12):3722-30
pubmed: 15308561
J Biol Chem. 2008 Apr 25;283(17):11535-40
pubmed: 18296709
Expert Opin Biol Ther. 2017 Jun;17(6):709-721
pubmed: 28375039
PLoS One. 2013 Oct 28;8(10):e74402
pubmed: 24204569
Anticancer Res. 2017 Jul;37(7):3717-3722
pubmed: 28668865
Cancer. 2003 Oct 15;98(8):1735-44
pubmed: 14534891
Cancer Treat Rev. 2008 Feb;34(1):92-101
pubmed: 17964729
J Exp Clin Cancer Res. 2015 Feb 05;34:10
pubmed: 25651794
Nature. 2000 Nov 30;408(6812):535-6
pubmed: 11117729
Curr Osteoporos Rep. 2007 Sep;5(3):98-104
pubmed: 17925190